SG11202007521PA - Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof - Google Patents

Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof

Info

Publication number
SG11202007521PA
SG11202007521PA SG11202007521PA SG11202007521PA SG11202007521PA SG 11202007521P A SG11202007521P A SG 11202007521PA SG 11202007521P A SG11202007521P A SG 11202007521PA SG 11202007521P A SG11202007521P A SG 11202007521PA SG 11202007521P A SG11202007521P A SG 11202007521PA
Authority
SG
Singapore
Prior art keywords
urea
linked
preparation
aromatic ring
substituted aromatic
Prior art date
Application number
SG11202007521PA
Inventor
Qiang Zhang
Shannan Yu
Zhongxiang Wang
Shouye Feng
Yansheng Liu
Xingfu Li
Hongbo Zhang
Leifu Yang
Hailong Yang
Likai Zhou
Nanqiao Zheng
Chenming Hu
Zhanqiang Xu
Original Assignee
Beijing Scitech Mq Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076232 external-priority patent/WO2018157730A1/en
Application filed by Beijing Scitech Mq Pharmaceuticals Ltd filed Critical Beijing Scitech Mq Pharmaceuticals Ltd
Priority claimed from PCT/CN2019/073259 external-priority patent/WO2019154132A1/en
Publication of SG11202007521PA publication Critical patent/SG11202007521PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
SG11202007521PA 2017-03-01 2019-01-25 Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof SG11202007521PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201710117662 2017-03-01
PCT/CN2018/076232 WO2018157730A1 (en) 2017-03-01 2018-02-11 Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
CN201810982631.6A CN110156802A (en) 2017-03-01 2018-08-27 The aromatic ring that urea replaces connects dioxanes and quinolines and the preparation method and application thereof
PCT/CN2019/073259 WO2019154132A1 (en) 2018-02-11 2019-01-25 Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof

Publications (1)

Publication Number Publication Date
SG11202007521PA true SG11202007521PA (en) 2020-09-29

Family

ID=63489805

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007521PA SG11202007521PA (en) 2017-03-01 2019-01-25 Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof

Country Status (5)

Country Link
US (1) US10980809B2 (en)
EP (1) EP3590941B1 (en)
CN (3) CN108530455B (en)
AU (2) AU2018226922B2 (en)
SG (1) SG11202007521PA (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110156804B (en) * 2018-02-11 2021-01-12 北京赛特明强医药科技有限公司 Dioxane quinoline compound and preparation method thereof
JP7018224B2 (en) 2018-02-11 2022-02-10 北京賽特明強医薬科技有限公司 Urea-substituted aromatic ring-bonded dioxynoquinoline compounds, their preparation methods and uses
WO2020042972A1 (en) * 2018-08-27 2020-03-05 北京赛特明强医药科技有限公司 Urea-substituted aromatic ring-linked dioxane and quinazoline or quinoline compound, composition and application thereof
CN111196814B (en) * 2018-11-19 2022-12-06 北京赛特明强医药科技有限公司 Aromatic ring-linked dioxane quinazoline or quinoline compound, composition and application thereof
CN112574176B (en) * 2019-09-27 2024-03-15 隆泰申医药科技(南京)有限公司 Heteroaryl compound and application thereof
CN112920240B (en) * 2021-01-26 2022-04-29 广东东阳光药业有限公司 Galactose-containing nitrogen-containing aromatic ring derivative and use thereof
CN112898360B (en) * 2021-01-26 2022-04-29 广东东阳光药业有限公司 Nitrogen-containing aromatic ring derivative containing glucose and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1382604T3 (en) * 2001-04-27 2006-04-18 Kirin Brewery Quinoline derivatives with an azolyl group and quinazoline derivatives
AU2003280599A1 (en) * 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
HUE032873T2 (en) 2008-03-17 2017-11-28 Ambit Biosciences Corp 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea as raf kinase modulator in the treatment of cancer diseases
CN102216300B (en) * 2009-09-30 2014-10-22 贝达药业股份有限公司 Compounds and compositions as protein kinase inhibitors
CN102532042A (en) * 2010-12-30 2012-07-04 上海医药工业研究院 Aryl urea compound as well as intermediate and application thereof
CN102311395B (en) * 2011-07-05 2014-04-16 张爱华 Quinazoline ring substituted diphenylurea derivative and its purpose
WO2013036232A2 (en) * 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
WO2014127214A1 (en) * 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN104530063B (en) * 2015-01-13 2017-01-18 北京赛特明强医药科技有限公司 Quinazoline and heterocyclic ring compounds, preparing method of compounds, and application of compounds serving as epidermal growth factor receptor inhibitors used for treating cancer
CN105837586B (en) 2015-12-14 2018-02-13 北京赛特明强医药科技有限公司 Dioxane and quinazoline aminated compounds and preparation method thereof and the application as epidermal growth factor receptor inhibitor
CN105884699B (en) * 2016-05-11 2019-05-07 中国药科大学 4- substituted aniline quinazoline derivative and its preparation method and application

Also Published As

Publication number Publication date
CN110156802A (en) 2019-08-23
AU2019218186A1 (en) 2020-09-10
EP3590941A1 (en) 2020-01-08
US20200061065A1 (en) 2020-02-27
AU2018226922B2 (en) 2020-12-24
CN108530455B (en) 2021-01-12
EP3590941B1 (en) 2023-11-22
CN108530455A (en) 2018-09-14
CN111757885B (en) 2021-01-29
AU2018226922A1 (en) 2019-10-03
US10980809B2 (en) 2021-04-20
CN111757885A (en) 2020-10-09
AU2019218186B2 (en) 2021-10-28
EP3590941A4 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
IL272089A (en) Compounds, compositions and methods
ZA201804362B (en) Mutant virus, preparation method therefor and application thereof
HK1255566A1 (en) Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
PL3676297T3 (en) Compounds, compositions and methods
EP3584239A4 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
SG11202007521PA (en) Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof
EP3246327A4 (en) 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof
IL272446A (en) Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
SG11202007554TA (en) Dioxazoline compound, preparation method therefor, and uses thereof
EP3398958A4 (en) Polyaminoacid, protein-polyaminoacid conjugate and preparation method therefor
EP3530694A4 (en) Polyester composition, preparation method therefor and application thereof
HK1255559A1 (en) Mg53 mutant, and preparation method therefor and uses thereof
EP3640248A4 (en) Aminopyrimidine compound, preparation method therefor and use thereof
EP3715342A4 (en) Fluorosulfonyl-containing compound, intermediate thereof, preparation method therefor and use thereof
EP3406602A4 (en) 1-sulfonamido-4-aryloxy compound, and preparation method and medicinal application thereof
EP3112351A4 (en) Naphthylamide compound, preparation method and use thereof
EP3447054A4 (en) Compound and preparation method therefor, composition and application thereof
EP3225627A4 (en) Tripeptide compound, preparation method therefor, and application thereof
EP3543248A4 (en) PHOSPHORESCENT PtAg2 COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOF
EP3360863A4 (en) Etomidate derivative and intermediate, preparation method and use thereof
EP3354648A4 (en) 4-substitued coumarin derivative, and preparation method and use thereof
IL282817A (en) Novel compound, preparation method and application thereof
ZA202004349B (en) Fluoralkenyl compounds, process for preparation and use thereof
EP3392263A4 (en) Polypeptide compound, preparation method therefor and use thereof
EP3395808A4 (en) Pseudo-ceramide compound and preparation method therefor